20 April 2018 - Fluad® influenza vaccine and risk to latex sensitive individuals
There are two trivalent influenza vaccines available through the 2018 National Influenza
Program for those aged 65 years and over: Fluad® (Seqirus) and Fluzone® (Sanofi
The Therapeutic Goods Administration (TGA) have confirmed the presence of natural
rubber latex in the needle sheath of the trivalent influenza vaccine Fluad® and have
advised that anyone with a severe allergy to latex should not receive Fluad®.
In addition to this, as a precautionary measure, SA Health is advising that anyone with a
known sensitivity or allergy to latex should not receive Fluad®.
There are no safety concerns regarding the Fluad® vaccine itself.
Fluzone® is latex free and can be used as alternative for those aged 65 years and over.
18 December 2017 - Hepatitis A Outbreak
Cases of hepatitis A continue to be reported in South Australia, with a further 6 cases reported in the last week. There have been a total of 19 notifications in 2017 and 13 since the 1st of November.
In this locally acquired outbreak men who have sex with men appear to be at highest risk, however local transmission to others can be expected.
Hepatitis A is spread through person-to-person transmission, including sexual activity, and through contaminated food and water. The incubation period is 15 to 50 days. Patients frequently experience fever, malaise, anorexia, right upper quadrant pain and nausea, followed a few days later by dark urine and jaundice. Cases are infectious for two weeks before to seven days after the onset of jaundice. There is no specific treatment and most cases fully recover, but ongoing monitoring is required as rarely complications, including fulminant hepatitis, can occur.